The human chloride/bicarbonate AE1 (anion exchanger) is a dimeric glycoprotein expressed in the red blood cell membrane, and expressed as an N-terminal ( 1-65) truncated form, kAE1 (kidney AE1), in the basolateral membrane of α-intercalated cells in the distal nephron. Mutations in AE1 can cause SAO (Southeast Asian ovalocytosis) or dRTA (distal renal tubular acidosis), an inherited kidney disease resulting in impaired acid secretion. The dominant SAO mutation ( 400-408) that results in an inactive transporter and altered eythrocyte shape occurs in many dRTA families, but does not itself result in dRTA. Compound heterozygotes of four dRTA mutations (R602H, G701D, V850 and A858D) with SAO exhibit dRTA and abnormal red blood cell properties. Co-expression of kAE1 and kAE1 SAO with the dRTA mutants was studied in polarized epithelial MDCK (Madin-Darby canine kidney) cells. Like SAO, the G701D and V850 mutants were predominantly retained intracellularly, whereas the R602H and A858D mutants could traffic to the basolateral membrane. When co-expressed in transfected cells, kAE1 WT (wild-type) and kAE1 SAO could interact with the dRTA mutants. MDCK cells co-expressing kAE1 SAO with kAE1 WT, kAE1 R602H or kAE1 A858D showed a decrease in cell-surface expression of the co-expressed proteins. When co-expressed, kAE1 WT colocalized with the kAE1 R602H, kAE1 G701D, kAE1 V850 and kAE1 A858D mutants at the basolateral membrane, whereas kAE1 SAO co-localized with kAE1 WT, kAE1 R602H, kAE1 G701D, kAE1 V850 and kAE1 A858D in MDCK cells. The decrease in cell-surface expression of the dRTA mutants as a result of the interaction with kAE1 SAO would account for the impaired expression of functional kAE1 at the basolateral membrane of α-intercalated cells, resulting in dRTA in compound heterozygous patients.
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INTRODUCTION
Members of the AE (anion exchanger) gene family are involved in intracellular pH homeostasis, cell volume regulation and the transport of bicarbonate across cell membranes. AE1 (Band 3) is a chloride/bicarbonate anion transporter expressed in the red blood cell membrane, and as an N-terminal truncated form in the basolateral membrane of α-intercalated cells in the collecting duct of distal nephrons [1] . The 911 amino acid human eAE1 (erythroid AE1) protein is encoded by the AE1 gene, which is located on chromosome 17q21-qter20 [2] . When AE1 is expressed using a different promoter, the kidney isoform of AE1 kAE1 (kidney AE1) is truncated by 65 amino acids at the N-terminal, resulting from the lack of erythroid exons 1-3 [3] .
Structurally, AE1 consists of two major domains. The 43 kDa N-terminal cytosolic domain is connected to the red blood cell cytoskeleton and contains binding sites for several glycolytic enzymes and haemoglobin. The 53 kDa C-terminal membrane domain spans the membrane 12-14 times and is responsible for the exchange of HCO 3 − for Cl − . Several AE1 mutations have been characterized in association with red blood cell abnormalities: HS (hereditary spherocytosis) [4] [5] [6] [7] [8] and SAO (Southeast Asian ovalocytosis) [9] [10] [11] , as well as a kidney disease, dRTA (distal renal tubular acidosis) [9] [10] [11] [12] [13] [14] [15] [16] [17] .
SAO is an asymptomatic hereditary red blood cell abnormality which is characterized by rigid, oval-shaped red blood cells and is widespread in Southeast Asian countries, such as Malaysia, Papua New Guinea, the Philippines and Indonesia [18] . SAO provides a barrier against cerebral malaria in children, accounting for its high frequency in some populations [19] . The mutation causing SAO results in a nine amino-acid deletion in AE1 at the boundary of the N-terminal cytoplasmic domain and the first transmembrane segment. The SAO deletion results in a misfolded protein which is inactive in anion transport [20, 21] and unable to bind anion transport inhibitors [22] . Recently, Cheung et al. [23] reported the loss of cell-surface expression and increased SAO turnover compared with AE1 WT (wild-type) when expressed in HEK-293 (human embryonic kidney) cells. SAO was detected at the plasma membrane after heterodimerization with AE1 WT, suggesting that AE1 WT protein can partially rescue the trafficking defect of the SAO protein.
Acid secretion in the kidney takes place in α-intercalated cells of distal tubules, where carbonic anhydrase II catalyses carbonic acid conversion into hydrogen and bicarbonate. Hydrogen ions are pumped out at the apical membrane via an H + -ATPase, whereas bicarbonate is exchanged for chloride by kAE1 at the basolateral membrane. dRTA is an inherited disease characterized by impaired urine acidification, metabolic bone disease, hypokalaemia and nephrocalcinosis. Mutations in kAE1 have been reported in both autosomal dominant and autosomal recessive dRTA [9] [10] [11] [12] [13] [14] [15] [16] [17] . Mutations which are known to cause dRTA are located within the transmembrane domain of kAE1. Dominant dRTA mutations include R589H, R589S, R589C, S613F, A858D, R901X and A888L/A889X, and recessive dRTA mutations include V488M, R602H, G701D, S773P and V850. Several dominant and recessive dRTA mutants have been [9, 11, 43] characterized by expression in HEK-293 and MDCK (MadinDarby canine kidney) cells [24] [25] [26] [27] [28] [29] [30] [31] . Dominant dRTA mutants are generally functional, but are retained in the ER (endoplasmic reticulum) or mislocalized to the apical membrane in transfected cells. Recessive dRTA mutants often have impaired functional expression when assayed in Xenopus oocytes [11, 17] and exhibit distinct trafficking defects in transfected cells [26, 27, 31, 32] .
Trafficking of the kAE1 G701D recessive mutant to the cell surface in oocytes is facilitated by the presence of GPA (glycophorin A), a major red cell membrane glycoprotein [11, 17] , which accounts for the lack of a red blood cell defect.
To date, the associations between dRTA and red blood cell disorders such as HS [33] and SAO [9, 11, 34] have been reported only for the recessive form of dRTA (Table 1) . Heterozygous kAE1 SAO with kAE1 WT does not cause dRTA [19] , suggesting that loss of one functional allele is not sufficient to cause dRTA. Patients who are compound heterozygotes of SAO and dRTA demonstrate both dRTA and haemolytic anaemia [11] . When expressed in Xenopus oocytes, the SAO AE1 protein was expressed at the plasma membrane [20] , however, in HEK-293 cells, kAE1 SAO showed a reduction in expression level and stability [23] . Homodimers of SAO were seen to be localized intracellularly in both non-polarized and polarized MDCK cells, whereas heterodimers of SAO and AE1 WT could traffic to the cell surface [23] .
Since the presence of SAO with dRTA in the opposite allele has been reported in Southeast Asian populations, dRTA mutants seem to possess a greater abnormality in the presence of SAO. Therefore the aim of the present study was to mimic the effect of SAO on dRTA mutants relative to the clinical manifestations of dRTA. Four different dRTA mutations, recessive R602H, G701D and V850, and the mildly dominant A858D, have been reported in compound heterozygous states with SAO [11, 34] (Table 1) . These patients display symptoms of complete dRTA and SAO with anaemia. In the present study, dRTA mutants were coexpressed with kAE1 WT or kAE1 SAO in MDCK cells in order to study the effect of their interaction on their trafficking to the cell surface. A recent study [24] showed that kAE1 WT could form heterodimers with kAE1 SAO and rescue the mutant proteins, allowing trafficking to the cell surface. Whereas kAE1 SAO can form a heterodimer with the kAE1 G701D dRTA mutant, this did not result in expression of the mutant at the cell surface.
In this present paper, we studied the effect of co-expression of kAE1 SAO on the expression of kAE1 WT and the dRTA mutants in MDCK cells, a model polarized cell system. Expressed alone, the kAE1 SAO protein was predominantly retained in the ER, whereas the dRTA mutants could exit the ER to varying degrees. We found that the kAE1 SAO mutant exerted a dominantnegative effect on the kAE1 WT and dRTA proteins, resulting in intracellular retention. However, the kAE1 WT protein could also partially rescue the trafficking of the kAE1 SAO mutant to the cell surface. The dominant effect of the kAE1 SAO protein is likely to be the result of heterodimer formation, which then affects the trafficking of the associated subunit.
MATERIALS AND METHODS

Viral production
Retroviral plasmids, pFBneo-kAE1-WT-Myc and pFBneo-kAE1-SAO-Myc, were generated by inserting an external Myc epitope at position 557. pFBneo-kAE1-WT-HA, pFBneo-kAE1-SAO-HA, pFBneo-kAE1-R602H-HA, pFBneo-kAE1-G701D-HA, pFBneo-kAE1-V850-HA and pFBneo-kAE1-A858D-HA viral plasmids were constructed as described previously [26] . HEK-293 cells (approx. 50-70 % confluent) were co-transfected with three retroviral plasmids, pVpack-GP (where GP is gag-pol genes), pVpack-VSV-G (vesicular-stomatitis-virus glycoprotein) and pFBneo-kAE1, using FuGENE TM 6 transfection reagent (Roche). The virus released into the supernatant was collected 2 days after transfection and filtered through 0.45 µm filters to remove the cell debris. Subconfluent MDCK cells were co-infected with virus encoding either kAE1 WT-Myc or kAE1 SAO-Myc and kAE1 or dRTA mutants containing the HA (haemagglutinin) tag in the presence of 8 µg/ml of polybrene (Sigma). Transfected MDCK cells were selected using 1 mg/ml Geneticin (G418; Sigma). Polarized MDCK cells expressing the various kAE1 constructs were grown on Transwell polycarbonate filters (Corning) for 4-5 days.
Western blots
Infected MDCK cells were lysed in PBS containing 1 % C 12 E 8 (octaethylene glycol mono-n-dodecyl ether) with protease inhibitors (1 µM leupeptin, 1 µM aprotinin, 1 µM pepstatin A and 200 µM PMSF) and centrifuged at 13 200 g for 15 min at 4
• C to remove insoluble material. The supernatant was resolved by SDS/PAGE (8 % gels) and transferred on to a nitrocellulose membrane. The tagged proteins were detected by using mouse anti-HA antibody (1:1000 dilution; Covance Research Products), followed by a secondary horseradish-peroxidase-conjugated goat anti-mouse antibody (1:1000 dilution; Cell Signaling Technology).
Immunofluorescence
Infected MDCK cells were grown on glass coverslips (nonpolarized cells) or on semi-permeable Transwell filters (polarized cells). The cells were fixed with 3.7 % (w/v) paraformaldehyde for 10 min, washed with 100 mM glycine, and permeabilized by incubating in 0.1 % Triton X-100 for 15 min. After blocking non-specific binding with 1 % BSA, the cells were incubated with either rabbit anti-Myc antibody (1:1000 dilution; Santa Cruz Biotechology) or mouse anti-HA antibody (1:1000 dilution; Covance Research Products) in 1 × PBS containing 1 % BSA for 30 min at room temperature (20 • C). After washing with 1 × PBS, Cy3-conjugated donkey anti-rabbit antibody (1:1000 dilution; Jackson ImmunoResearch Laboratories) and Alexa Fluor ® 488-conjugated goat anti-mouse (1:1000) antibody (Molecular Probes) were incubated with the cells for 30 min at room temperature. The staining was observed using a laser confocal LSM 510 microscope (Zeiss).
Co-immunoprecipitation
kAE1 WT-Myc or kAE1 SAO-Myc was co-expressed with HAtagged kAE1 WT, kAE1 SAO or the dRTA mutants in MDCK cells. Confluent MDCK cells in 100 mm 2 dishes were lysed in PBS containing 1 % C 12 E 8 with protease inhibitors. kAE1 WTMyc or kAE1 SAO-Myc and the associated kAE1 WT or dRTA mutant proteins were precipitated by incubation with rabbit antiMyc antibody (1:250 dilution) for 1 h, followed by Protein GSepharose. Western blot analysis was used to reveal any protein associated with either kAE1 WT-Myc or kAE1 SAO-Myc by blotting using an anti-HA antibody.
Biotinylated His 6 -tagged co-purification
Cell-surface biotinylation was used to detect proteins present at the cell surface, and this was combined with His 6 -tagged copurification to identify heterodimers of proteins [27] . HEK-293 cells were co-transfected with either eAE1 WT-His 6 or eAE1 SAO-His 6 and with kAE1 WT, kAE SAO or dRTA mutants. The His 6 tag was located at the C-terminal of the proteins to facilitate their purification, the tag having little effect on protein expression [23, 28] . To biotinylate the cell-surface proteins, the transfected HEK-293 cells were labelled with 0.5 mg of membraneimpermeable biotinylating EZ-Link NHS-LC-Biotin [sulfosuccinimidyl-6-(biotinamido)hexanoate] (Pierce) in borate buffer [10 mM boric acid (pH 9.0), 154 mM NaCl, 7.2 mM KCl, and 1.8 mM CaCl 2 ] for 15 min at 4
• C, following by quenching of the unreacted biotin with excess glycine [29] . After cell lysis in 1 % C 12 E 8 , eAE1 WT-His 6 or eAE1 SAO-His 6 and any associated kAE1 or dRTA mutant proteins were captured using ProBond TM Ni 2+ beads (Invitrogen) by incubating for 1 h at 4
• C. The protein was eluted in 500 mM imidazole, and kAE1 proteins were detected by immunoblotting. Rabbit polyclonal anti-(Nt eAE1) and anti-(Nt kAE1) (where Nt is N-terminal) antibodies [28] (both at 1:500 dilution) were used to detect eAE1 and kAE1 respectively, whereas horseradish-peroxidase-conjugated antibiotin antibody (1:1000 dilution; Cell Signaling Technology) was used to visualize biotinylated AE1, detecting proteins which were expressed at the cell surface. Rabbit polyclonal anti-(Ct AE1) antibody (1:500 dilution) (where Ct is C-terminal), which does not detect proteins containing a His 6 tag at the C-terminal [28] , detected kAE1 WT or or kAE1 mutants that were associated with eAE1 WT-His 6 or eAE1 SAO-His 6 . The erythroid and kidney isoforms, which run at different molecular masses, were used to distinguish the co-expressed proteins resolved by SDS/PAGE (8 % gels).
FACS analysis
MDCK cells co-expressing either kAE1 WT-HA or kAE1 SAO-HA with kAE1 WT, kAE SAO or the dRTA mutants were trypsinized for 5 min at 4
• C, centrifuged at 16 000 g for 4 min at 4
• C to collect the cells and resuspended in HBSS (Hanks balanced salt solution) supplemented with 1 % BSA. The cells were fixed by incubating in 3.7 % (w/v) paraformaldehyde for 10 min, and washed once with 100 mM glycine. To determine the amount of cell-surface expression (by detecting HA-tagged proteins), cells were incubated with mouse anti-HA antibody (1:1000 dilution) in HBSS + 1 % BSA for 15 min. An Alexa Fluor ® 488-conjugated goat anti-mouse antibody (1:1000; Molecular Probes) was subsequently used to probe for mouse anti-HA antibody by incubating for 15 min on ice. All samples were washed with HBSS + 1 % BSA and analysed using a Beckman Coulter EPICS Elite flow cytometer.
RESULTS
Expression of kAE1 SAO and dRTA mutants in MDCK cells
To determine the expression of HA-tagged kAE1 SAO and dRTA mutants in MDCK cells, immunoblot analysis of whole-cell extracts ( Figure 1 ) using an anti-HA antibody was performed. Previous studies [26] have shown that the upper bands detected by immunoblot corresponded to kAE1 modified with complex oligosaccharides, whereas the lower band was kAE1 modified with high mannose oligosaccharides. The complex form of kAE1 had escaped the ER and moved to the Golgi/cell surface, whereas the high mannose form was in the ER [29] . Samples were treated with endoglycosidase H to shift the lower band and to enhance the separation from the upper complex bands. The blot shows that the majority of kAE1 WT is modified with complex oligosaccharides (upper bands) and a small amount is modified with high mannose oligosaccharides (lower band). kAE1 SAO is poorly expressed relative to the kAE1 WT protein, and is not strongly associated with complex oligosaccharides, suggesting that most of the protein is retained in the ER (see below). Like kAE1 WT, kAE1 R602H and the mildly dominant kAE1 A858D mutants are mostly modified with complex oligosaccharides and with a small amount of high mannose oligosaccharides, indicating that these constructs have exited efficiently from the ER. Recessive kAE1 G701D and kAE1 V850 mutants show modification with both complex and high mannose oligosaccharides; however, the expression of the complex oligosaccharide band of both mutants is lower than that for kAE1 WT, especially for the kAE1 G701D mutant. Scans of the blots revealed that the level of complex glycosylated protein as a percertage of total protein was 88 % for kAE1 WT, 17 % for kAE1 SAO, 86 % for kAE1 R602H, 32 % for kAE1 G701D, 60 % for kAE1 V850 and 84 % for kAE1 A858D. The diffuse nature of the complex bands may result in underestimation of this form, especially for kAE1 SAO and kAE1 G701D, which are expressed at lower levels. These results confirm findings from previous studies [26, 27] , which determined that kAE1 WT and kAE1 A858D can efficiently exit the ER and move to the medial Golgi, whereas kAE1 G701D and kAE1 V850 are impaired in ER exit. The misfolded kAE1 SAO mutant is largely retained in the ER when expressed in MDCK cells, as reported previously [23] .
Immunolocalization of kAE1 WT, kAE1 SAO and the dRTA mutants was performed in polarized MDCK cells (Figure 1B) . kAE1 WT was localized to the basolateral membrane, whereas kAE1 SAO was localized intracellularly. The recessive kAE1 R602H mutant and the dominant kAE1 A858D mutant were mainly found at the basolateral membrane of polarized MDCK cells. kAE1 G701D and kAE1 V850 were predominantly localized intracellularly, with some basolateral staining. Previous studies [26] showed that kAE1 WT co-localized with E-cadherin, a basolateral maker, as did the majority of kAE1 A858D; kAE1 SAO and kAE1 V850 with calnexin, an ER marker; and kAE1 G701D with giantin, a Golgi marker.
Heterodimers of kAE1 SAO with dRTA mutants in epithelial MDCK cells
Heterodimers of kAE1 WT and dRTA mutants can form when co-expressed in HEK-293 [28, 29] and MDCK cells [26] . Since patients who are compound heterozygous for SAO and dRTA mutants have been shown to exhibit dRTA (Table 1) , heterodimer formation between the two proteins was studied by co-immunoprecipitation from MDCK cells expressing kAE1 WT-Myc or kAE1 SAO-Myc together with HA-tagged versions of kAE1 WT, kAE1 SAO and the dRTA mutants (kAE1 R602H,
Figure 1 Expression of dRTA mutants in MDCK cells
(A) Immunoblot analysis of whole-cell extracts from MDCK cells expressing kAE1 WT-HA (kWT.HA), kAE1 SAO-HA (kSAO.HA) and HA-tagged dRTA mutants kAE1 R602H (kR602H.HA), kAE1 G701D (kG701D.HA), kAE1 V850 (kdV850.HA) or kAE1 A858D (kA858D.HA). The proteins were detected using a mouse anti-HA antibody, followed by a horseradish-peroxidase-conjugated goat anti-mouse antibody. All samples were treated with endoglycosidase H in order to remove the oligosaccharide from the high mannose form of kAE1 (open circle) and enhance separation from the complex oligosaccharide forms (closed circle). (B) Localization of HA-tagged kAE1 WT-HA (kWT.HA), kAE1 SAO-HA (kSAO.HA) and HA-tagged dRTA mutants kAE1 R602H (kR602H.HA), kAE1 G701D (kG701D.HA), kAE1 V850 (kdV850.HA) or kAE1 A858D (kA858D.HA) in polarized MDCK cells. The cells were fixed, permeabilized and stained with mouse anti-HA antibody, followed by Alexa Fluor ® 488-conjugated goat anti-mouse antibody. The confocal images were captured using a Zeiss LSM 510 confocal microscope. kAE1 G701D, kAE1 V850 and kAE1 A858D). Myc-tagged kAE1 WT (Figure 2A ) or kAE1 SAO ( Figure 2B ) was immunoprecipitated using rabbit anti-Myc antibody, and any associated HA-tagged proteins were detected by immunoblotting using mouse anti-HA antibody.
The immunoprecipitated fraction in Figure 2 (A) showed dimer formation between kAE1 WT-Myc and kAE1 WT-HA (lane 1), as expected for the formation of kAE1-AE1 dimers. The HAtagged kAE1 WT protein that was co-immunoprecipitated with kAE1 WT-Myc contained both complex and high mannose oligosaccharide forms, with the majority of the protein associated with the complex form. The presence of the high mannose form indicated that kAE1 forms dimers in the ER. Control immunoprecipitates of cells which were transfected with only the HAtagged constructs without tagged kAE1 WT did not show any kAE1 WT bands on the HA blot (results not shown).
When kAE1 WT-Myc was co-expressed with kAE1 SAO-HA, the yield of co-immunoprecipitated kAE1 SAO-HA was very low compared with the co-expression of kAE1 WT proteins (Figure 2A ). This is likely to be the result of poor expression of kAE1 SAO. It is also possible that homodimerization of kAE1 WT proteins may be preferable over heterodimerization with the misfolded kAE1 SAO mutant.
Co-immunoprecipitation of kAE1 WT-Myc with the HAtagged dRTA mutants (kAE1 R602H, kAE1 G701D, kAE1 V850 and kAE1 A858D) was detected for all of the dRTA mutants. The kAE1 R602H mutant protein which co-immunoprecipitated with kAE1 WT (Figure 2A ) contained both complex and high mannose oligosaccharide forms, similar to the kAE1 WT pull-down, indicating that the kAE1 R602H mutant had little effect on the trafficking of kAE1 WT. The kAE1 G701D and kAE1 V850 mutants (Figure 2A ) had less complex oligosaccharides present relative to high mannose oligosaccaharides, consistent with poor ER exit of these mutants ( Figure 1 ) and retention of kAE1 WT. The kAE1 A858D mutant had a pattern similar to kAE1 WT, indicating that this mutant had little effect on kAE1 WT trafficking. The results indicate that heterodimers of kAE1 WT can form with kAE1 SAO and dRTA mutants, and that the mutants vary in their ability to retain kAE1 WT in the ER, with kAE1 SAO having the strongest effect, followed by the kAE1 G701D and kAE1 V850 mutants, with kAE1 R602D and kAE1 A858D having little effect. V850 (kdV850.HA) or kAE1 A858D (kA858D.HA) were lysed in 1 % C 12 E 8 and extracts were immunoprecipitated (IP) with rabbit anti-Myc antibody and Protein G-Sepharose. The bound proteins were eluted from the resin using 2× Laemmli buffer. Immunoblotting (WB) using the mouse anti-HA antibody was used to detect associated HA-tagged proteins. Closed circles represent AE1 protein that was modified with the addition of complex oligosaccharide, whereas open circles indicate AE1 protein modified with the addition of the high mannose oligosaccharide. All samples were treated with endoglycosidase H in order to remove the oligosaccharide from the high mannose form of kAE1 (lower band) and enhance the separation from the upper complex forms.
To mimic the compound heterozygous state of kAE1 SAO and dRTA mutants, kAE1 SAO-Myc was co-expressed with kAE1 WT, kAE1 SAO and the dRTA mutants (kAE1 R602H, kAE1 G701D, kAE1 V850 and kAE1 A858D) in MDCK cells ( Figure 2B ). The immunoprecipitation of kAE1 SAO-Myc with rabbit anti-Myc antibody was performed, and the associated HA-tagged kAE1 proteins were detected using mouse anti-HA antibody. The co-immunoprecipitation of kAE1 SAO-Myc with kAE1 WT showed that the majority of kAE1 WT was the complex oligosaccharide-modified form, but there was also some of the high mannose-modified form present. This shows that kAE1 SAO retains some kAE1 WT in the ER, but that heterodimers can also exit in the ER. Co-expression of kAE1 SAO-Myc with kAE1 SAO-HA was also shown to be predominantly high mannosemodified, as expected, since very little kAE1 SAO can exit the ER. This demonstrated that misfolded kAE1 SAO can form homodimers.
Co-immunoprecipitation of kAE1 SAO-Myc with HA-tagged versions of the dRTA mutants showed an increase in the amount of the high mannose forms relative to the complex oligosaccaride forms for all the dRTA mutants ( Figure 2B ) relative to coexpression of the mutants with kAE1 WT (Figure 2A ). kAE1 SAO retained in the ER can interact with high mannose forms of kAE1 WT or dRTA mutants. Thus the kAE1 SAO mutant exhibits a dominant-negative effect, retaining associated dRTA mutants in the ER, and this is likely to be the result of heterodimer formation. In the case of kAE1 WT, kAE1 R602H, kAE1 V850 and kAE1 A858D, the presence of the complex oligosaccaride-modified forms of these proteins associated with kAE1 SAO indicates that these proteins can facilitate the exit of SAO from the ER.
eAE1 WT rescues the expression of recessive mutants, whereas eAE1 SAO inhibits the trafficking of kAE1 R602H and kAE1 A858D to the cell surface in HEK-293 cells
To determine whether SAO could affect the trafficking of dRTA mutants to the cell surface, eAE1 WT-His 6 or eAE1 SAO-His 6 were co-expressed in HEK-293 cells with kAE1 WT, kAE1 SAO and the dRTA mutants kAE1 R602H, kAE1 G701D, kAE1 V850 and kAE1 A858D. The larger eAE1 form was used to identify co-expressed proteins on immunoblots (Figure 3 ). HEK-293 cells were used for these experiments, since in these cells little or no processing of the high mannose to complex oligosaccharide on AE1 occurs. Thus mainly high mannose bands are present, simplifying the analysis. HEK-293 cells were subjected to biotinylation to label proteins expressed at the cell surface. After cell-surface biotinylation, eAE1 WT-His 6 or eAE1 SAOHis 6 and associated kAE1 proteins were subsequently purified by ProBond TM Ni 2+ beads. Figure 3(A) is an immunoblot performed using both anti-(Nt eAE1) and anti-(Nt kAE1) antibodies, which shows the overall expression levels of both proteins. The level of eAE1 WT ( Figure 3A , left-hand panel, upper bands) was higher than eAE1 SAO ( Figure 3A , right-hand panel, upper bands) as a result of the poor expression of SAO. The level of expression of the His 6 -tagged proteins ( Figure 3A , upper bands) was similar to the level of the non-His 6 -tagged proteins ( Figure 3A, lower bands) , showing that the C-terminal His 6 tag did not have a major effect on AE1 expression. Figure 3 (B) is an immunoblot of the eluate of the Ni 2+ column using an anti-(Ct AE1) antibody. The His 6 tag at the C-terminal of eAE1 WT or eAE1 SAO blocked binding of the anti-(Ct AE1) antibody, therefore only non-His 6 -tagged AE1 proteins associated with His 6 -tagged eAE1 WT or eAE1 SAO are detected. The results show that kAE1 WT, kAE1 SAO, kAE1 R602H, kAE1 G701D, kAE1 V850 and kAE1 A588D can all form heterodimers with eAE1 WT-His 6 ( Figure 3B, left-hand panel) or eAE1 SAO-His 6 ( Figure 3B, right-hand panel) . There was a small amount of an upper band present when eAE1 WT was co-immunoprecipitated with kAE1 WT and some of the kAE1 mutants, and this corresponded to the presence of some complex oligosaccharide.
Figure 3(C) shows the biotinylated protein found in the fraction bound to the Ni 2+ column. The upper band represents His 6 -tagged eAE1 that was present at the cell surface and biotinylated. It represents homodimers of eAE1 WT and also heterodimers of eAE1 with the kidney forms. The lower band represents kAE1 proteins which are associated with His 6 -tagged eAE1. These proteins represent heterodimers with the eAE1 WT protein that are present at the cell surface and biotinylated. The His 6 -tagged eAE1 WT could be detected in the biotinylated fraction ( Figure 3C , left-hand panel, upper band). Associated biotinylated bands corresponding to kAE1 WT, kAE1 SAO and the dRTA mutants could also be detected ( Figure 3C , left-hand panel, lower band), showing that these mutants can be found associated with eAE1 WT at the cell surface. The level of biotinylation detected for the lower kidney forms for some mutants (e.g. kAE1 R602D) was more intense than the upper erythroid form, suggesting that the kidney form was more heavily biotinylated, or that the erythroid form was associated with more than just one kAE1 protein monomer. The bands corresponding to kAE1 SAO and kAE1 G701D were poorly biotinylated compared with other dRTA mutants. This may be the result of either poor cell-surface expression even when these mutants were co-expressed with the eAE1 WT protein or a weak reaction of these mutants with the biotinylation reagent (see below). Nevertheless, biotinylated kAE1 SAO was detected in association with eAE1 WT, showing that the eAE1 WT protein could partially rescue the trafficking of the SAO mutant to the cell surface. Figure 3 (C) (right-hand panel) shows the biotinylated proteins found in association with eAE1 SAO at the cell surface. A low level of biotinylated eAE1 SAO-His 6 was observed in all cases, whereas some of the associated proteins (kAE1 WT and kAE1 A858D) showed strong biotinylation. Since the kAE1 WT and kAE1 A858D mutant proteins were isolated by virtue of their association with the His 6 -tagged eAE1 SAO mutant, this indicated that the eAE1 SAO protein must have been present at the cell surface, but was poorly biotinylated. SAO is a misfolded protein, which reacts poorly with stilbene disulfonates as a result of a less reactive lysine residue [35] . The same reactive lysine residue may be responsible for the majority of the biotinylation reaction [36] , resulting in poor biotinylation of the eAE1 SAO mutant. The strong signal observed for kAE1 WT in association with eAE1 SAO shows that the kAE1 WT protein can be found as a dimer with eAE1 SAO at the cell surface. A similar observation was made with co-expression of eAE1 SAO and the mildly dominant kAE1 A858D mutant. In contrast, weak biotinylation signals were detected for kAE1 SAO, kAE1 R602H, kAE1 G701D and kAE1 V850 mutants, showing that they were poorly biotinylated or poorly expressed at the cell surface in association with eAE1 SAO. The SAO protein is likely to retain these dRTA mutants intracelluarly, in contrast with the kAE1 WT and kAE1 A858D mutant proteins, which can be found at the cell surface in association with eAE1 SAO. kAE1 WT and kAE1 A858D, but not the other dRTA mutants, can rescue the trafficking of the eAE1 SAO mutant to the cell surface.
Decreased cell-surface expression of dRTA mutants when co-expressed with kAE1 SAO in MDCK cells
The impaired cell-surface expression of the dRTA mutants when co-expressed with SAO was confirmed using flow cytometry (Figure 4) . MDCK cells expressing a combination of either kAE1 WT-Myc or kAE1 SAO-Myc with HA-tagged kAE1 WT or mutants (kAE1 R602H-HA, kAE1 G701D-HA, kAE1 V850-HA and kAE1 A858D-HA) were prepared. The HA tag inserted at position 557 of the third extracellular loop of AE1 was used to monitor the surface-expressed protein. The presence of proteins at the cell surface was detected using the Alexa Fluor ® 488-conjugated secondary antibody. The fluorescence intensities of MDCK cells expressing kAE1 were heterogeneous, with some cells expressing high levels of protein. The mean fluorescence intensities of kAE1 WT-HA, kAE1 R602H-HA and kAE1 A858D-HA when expressed alone were 15.5, 7.69 and 7.78 respectively (n = 5), showing that these proteins can traffic to the cell surface, with a lower level of cell-surface expression of the two mutants relative to kAE1 WT. The kAE1 SAO-HA, kAE1 G701D-HA and kAE1 V850-HA mutants when expressed alone gave an even lower level of mean fluorescence intensity (3.4, 3.82 and 3.7 respectively, n = 5), indicating a seriously diminished level of cell-surface expression. The average background of mean fluorescence intensity of uninfected MDCK cells was 2.78 (n = 6). Co-expression of kAE1 WT had little effect on the average level of cell-surface expression of HA-tagged kAE1 WT (14 compared with 15.5). Co-expression of kAE1 SAO reduced the average level of cell-surface expression of HA-tagged kAE1 WT (6.38), and the fluorescence intensity profiles of these cells were slightly lower than those obtained on co-expression of the kAE1 WT proteins.
Co-expression of the kAE1 WT protein with HA-tagged kAE1 SAO did not result in significant rescue of the kAE1 SAO mutant (3.69 compared with 3.4) as determined by flow cytometry. As expected, co-expression of the kAE1 SAO mutant with HAtagged kAE1 SAO did not result in cell-surface expression of the tagged protein. This was similarly observed with the combination of kAE1 SAO and HA-tagged versions of kAE1 G701D (3.92 compared with 3.82 for kAE1 G701D alone) and kAE1 V850 (3.87 compared with 3.7 for kAE1 V850 alone) mutants. Co-expression with the kAE1 WT protein resulted in modest enhancement of cell-surface expression of the kAE1 G701D (4.32 compared with 3.82 for kAE1 G701D alone) and kAE1 V850 (4.4 compared with 3.7 for kAE1 V850 alone) mutants. In the cases of the kAE1 R602H and kAE1 A858D mutants, co-expression with the kAE1 SAO mutant resulted in less cell-surface expression compared with expression of the kAE1 R602H and kAE1 A828D mutants alone (5.78 compared with 7.69 and 4.4 compared with 7.78 respectively), whereas co-expression with the kAE1 WT protein had little effect on cell-surface expression of these mutants. Expression with kAE1 SAO had a significant effect on the fluorescence intensity curves of the kAE1 R602H mutant, reducing the population of highly fluorescent cells. These results show that co-expression of the kAE1 SAO mutant results in a modest decrease in the cell-surface expression of kAE1 WT, with a greater effect on the kAE1 R602D and kAE1 A858D mutants. The kAE1 SAO mutant did not rescue the kAE1 G701D and kAE1 V850 mutants, which are retained intracellularly. The compound heterozygote of kAE1 SAO with dRTA mutants does not reach the cell surface of MDCK cells
The localization of kAE1 WT-Myc co-expressed with HA-tagged dRTA mutants in polarized MDCK cells was studied by confocal microscopy ( Figure 5A ). Strong co-localization of kAE1 WT-HA and kAE1 WT-Myc was exhibited at the basolateral surface of polarized MDCK cells. When co-expressed with the kAE1 SAO mutant, some of the kAE1 SAO mutant co-localized with kAE1 WT-Myc at the basolateral membrane, but there was significant intracellular co-localization, indicating that the kAE1 SAO mutant could retain kAE1 WT inside the polarized cells. A similar observation was made with the kAE1 G701D and kAE1 V850 mutants when co-expressed with kAE1 WT, showing some colocalization at the cell surface, but also some intracellular staining. In contrast, there was a sharp co-localization of the kAE1 R602H and the kAE A858D mutants with the kAE1 WT protein at the basolateral membrane, again indicating that these co-expressed proteins can efficiently traffic to the cell surface. Polarized MDCK cells co-expressing kAE1 SAO-Myc with kAE1 WT-HA and HA-tagged dRTA mutants were examined by immunostaining. kAE1 WT-HA, when co-expressed with kAE1 SAO-Myc was localized to the basolateral membrane, but was also found intracellularly ( Figure 5B) , showing that the kAE1 SAO mutant could retain the kAE1 WT protein, and this was likely to be the result of heterodimer formation. Co-expression of kAE1 SAO-Myc with kAE1 SAO-HA showed intracellular localization in polarized MDCK cells. The HA-tagged dRTA mutants kAE1 R602H, kAE1 G701D, kAE1 V850 and kAE1 A858D, all showed strong intracellular co-localization with the kAE1 SAO mutant when co-expressed with the kAE1 SAO mutant in polarized MDCK cells. The kAE1 R602H and kAE1 A858D mutants also showed some level of co-expression with the kAE1 SAO mutant at the basolateral membrane. No co-localization of kAE1 SAO at the basolateral membrane was observed with the kAE1 G701D and kAE1 V850 mutants. The results show that the kAE1 WT protein can partially rescue the basolateral expression of kAE1 SAO and the dRTA mutants in polarized MDCK cells, and that co-expression of the kAE1 SAO mutant promotes intracellular retention of kAE1 WT and the dRTA mutants.
DISCUSSION
The molecular pathophysiology of autosomal dominant and recessive dRTA has been studied in various cell types [11, 17, 26, 29, 31, 37] . Polarized MDCK cells serve as a good model for understanding the process occurring in epithelial kidney cells [25] . In the kidney, kAE1 is targeted to the basolateral membrane of α-intercalated cells in the distal nephron, where it exchanges chloride for bicarbonate to reabsorb bicarbonate into the blood ( Figure 6A ). Autosomal dominant and recessive dRTA can be caused by mutations in the AE1 gene. Dominant mutants (R589H, G609R, S613F, A858D and R901X) have reduced levels of cell-surface expression, but retain transport activity [11, 12, [28] [29] [30] [31] 37, 38] . Different dominant dRTA mutants may act by different mechanisms, either by mistargeting to the apical surface of polarized MDCK cells [30, 37] or by causing a dominantnegative effect, retaining the WT protein intracellularly in the ER [28] (Figure 6C ). Kidney AE1 exists as a dimer, and the R589H and R901X dominant mutants are able to form heterodimers with kAE1 WT, causing intracellular retention of kAE1 WT [28, 29] . R901X, a mutant missing the C-terminal 11 amino acids of kAE1 WT, is also reported to exhibit mis-routing to the apical membrane in polarized MDCK and LLC-PK1 cells [37, 38] . Likewise, the G609R mutant is reported to be misdirected to both apical and basolateral membranes of polarized MDCK cells [30] . However, the A858D mutant, a mildly dominant and misfolded mutant, is able to escape ER quality control and traffic to the basolateral membrane of polarized MDCK cells [39] .
In heterozygotes, the recessive dRTA mutants (R602H, G701D and V850) do not cause complete dRTA. Recessive dRTA mutants appear to be defective in chloride/bicarbonate exchange activity; however, the expression of the WT allele is sufficient to mediate transport activity. In addition, misfolded recessive mutants may be targeted for degradation, limiting heterodimer formation. Heterodimers of the WT protein with recessive dRTA mutants can traffic to the cell surface, and the WT protein can retain functionality even when associated with an impaired subunit, as in the case of SAO heterodimers.
Red blood cells of patients that are compound heterozygotes of SAO with the R602H, G701D, V850 or A858D mutations are more rigid than simple SAO [11] . Compound heterozygous cells carrying both R602H with SAO were reported in a Thai family exhibiting a reduction in sulfate uptake. In compound heterozygous cells carrying both G701D and SAO, similar effects were shown, as there was loss of cell-surface expression and no chloride transport activity in Xenopus oocytes [11] . Similarly, no transport activity was observed in Xenopus oocytes of compound heterozygote cells carrying both V850 and SAO, and the compound heterozygote A858D and SAO exhibited diminshed transport activity relative to expression of the A858D mutant alone [11] . AE1 SAO is known to affect the structure and function of AE1 WT through heterodimer formation. It was hypothesized that SAO may disrupt the structure of a mutant partner subunit in heterodimers [36] and affect trafficking, as SAO is defective in trafficking to the cell surface in polarized MDCK cells [23] . In red blood cell precursors, GPA facilitates AE1 trafficking to the cell surface, including the AE1 G701D mutant [17] . Moreover, coexpression of GPA increases the rate of trafficking of SAO to the oocyte membrane [11] . With the SAO compound heterozygotes, the G701D, V850 and A858D mutants were able to rescue plasma membrane expression and increased 36 Cl − influx activity when co-expressed with GPA [11, 17] .
In this present paper, we have studied the effect of coexpression of dRTA mutants with kAE1 WT or with AE1 SAO. In heterozygotes with recessive dRTA mutations and kAE1 WT, the R602H and A858D mutants were co-localized at the basolateral membrane in polarized MDCK cells. In contrast, the G701D and V850 mutants predominantly retained the WT protein intracelluarly. However, some of these mutants were also colocalized at the basolateral membrane with the WT protein. The co-expression of SAO with the WT protein reduced the level of cell-surface expression of the WT protein, showing that the SAO mutant had a dominant effect on the WT protein. The SAO mutant decreased the cell-surface expression of the recessive R602H mutant and the mildly dominant A858D mutant that can traffic to the cell surface when expressed alone. However, there was some co-localization of the WT and SAO proteins at the cell surface, indicating that the WT protein can also promote cell-surface expression of the SAO mutant, and this is likely to be through the formation of heterodimers. Co-expression of the SAO mutant with the traffic-impaired G701D and V850 mutants did not result in cell-surface expression, but also did not rescue the intracellular retention of the mutants. In contrast, co-expression of the WT protein with these two recessive mutants did allow some rescue of the dRTA mutants to the cell surface. Figure 6 illustrates the four situations that were studied in this paper. In the first case, kAE1 WT ( Figure 6A ) is synthesized in the ER and is trafficked normally through the Golgi to the basolateral membrane of polarized epithelial cells as a dimer. In the case of SAO (Figure 6B ), when the mutant is expressed alone, it is retained in the ER, and this is likely to be as a misfolded homodimer in association with molecular chaperones, such as calnexin [40] . However, when co-expressed with the WT protein ( Figure 6B ), the SAO protein forms heterodimers that retain some of the WT protein in the ER, but also allows some SAO protein to traffic to the basolateral membrane. Since the SAO protein is non-functional, this may result in a decrease in the level of functional AE1 at the basolateral membrane, but this reduction or mistargeting to the apical membrane is not sufficient to cause dRTA in SAO patients. In the case of the recessive dRTA mutants (Figure 6C ), the mutants exhibit various degrees of impaired trafficking to the basolateral membrane of polarized cells. The WT protein is able to rescue trafficking of the recessive dRTA mutants, resulting in sufficient anion transport activity to avoid a dRTA phenotype in heterozygotes. In the fourth case, coexpression of the non-functional SAO mutant with the recessive dRTA mutants ( Figure 6D ) results in enhanced intracellular retention of the dRTA mutants and, importantly, no rescue of these mutants to the basolateral membrane. This accounts for the severe dRTA phenotype seen in SAO/dRTA compound heterozygotes, as little or no functional protein would be present in the basolateral membrane of α-intercalated cells in the kidneys of these compound heterozygous patients.
